Clinical trial • Phase III • Infectious Disease
Aztreonam | Avibactam for Sepsis
Phase III trial of Aztreonam | Avibactam for Sepsis. 16 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Sepsis
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 05-12-2025
- First CTIS Authorization Date
- 22-03-2026
Trial design
Phase III trial across 1 site in Austria.
- Target Sample Size
- 16
Eligibility
Recruits 16 Vulnerable population selected; no details on consent or assent provided in the available documents..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent provided in the available documents.
Recruitment
- Planned Sample Size
- 16
- Recruitment Window Months
- 11
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 16
Austria
- Earliest CTIS Part Ii Submission Date
- 09-03-2026
- Latest Decision Or Authorization Date
- 22-03-2026
- Processing Time Days
- 13
- Number Of Sites
- 1
- Number Of Participants
- 16
Sites
- Site Name
- Medical University Of Vienna
- Department Name
- Department of Clinical Pharmacology
- Contact Person Name
- Markus Zeitlinger
- Contact Person Email
- markus.zeitlinger@meduniwien.ac.at
- Number Of Participants
- 16
Sponsor
Primary sponsor
- Full Name
- Medical University Of Vienna
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Austria
Investigational products
- Investigational Product Name
- Aztreonam-Avibactam
- Active Substance
- Aztreonam | Avibactam
- Modality
- Small molecule
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.